Download PDF
Thromb Haemost 1995; 73(01): 101-105
DOI: 10.1055/s-0038-1653732
Original Article
Coagulation
Schattauer GmbH Stuttgart

Evaluation of Recombinant Human Factor IX: Pharmacokinetic Studies in the Rat and the Dog

James C Keith Jr
The Departments of Preclinical Research and Development, Genetics Institute, Inc., Cambridge, MA, USA
,
Thomas J Ferranti
The Departments of Preclinical Research and Development, Genetics Institute, Inc., Cambridge, MA, USA
,
Bibhu Misra
The Departments of Preclinical Research and Development, Genetics Institute, Inc., Cambridge, MA, USA
,
Thomas Frederick
The Departments of Preclinical Research and Development, Genetics Institute, Inc., Cambridge, MA, USA
,
Bonita Rup
The Departments of Preclinical Research and Development, Genetics Institute, Inc., Cambridge, MA, USA
,
Kyle McCarthy
The Departments of Preclinical Research and Development, Genetics Institute, Inc., Cambridge, MA, USA
,
Robert Faulkner
The Departments of Preclinical Research and Development, Genetics Institute, Inc., Cambridge, MA, USA
,
Larry Bush
1   The Department of Formulation Process Development, Genetics Institute, Inc., Cambridge, MA, USA
,
Robert G Schaub
The Departments of Preclinical Research and Development, Genetics Institute, Inc., Cambridge, MA, USA
› Author Affiliations
Further Information

Publication History

Received 14 July 1994

Accepted after revision 09 September 1994

Publication Date:
27 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The pharmacokinetics of intravenously administered recombinant human factor IX (rhFIX) were studied in Sprague-Dawley rats and Beagle dogs. Rats received rhFIX (50 IU/kg once daily) for 28 days, and the plasma half-life was 5 h. Anti-Human Factor IX serum antibody levels were found in only 1 of 12 rats. The pharmacokinetic profiles of rhFIX or Mononine™, a purified human plasma-derived factor IX, after single 100 IU/kg IV doses in dogs, were similar. Peak plasma concentrations of rhFIX and Mononine™ were 4–5 μg/ml. The mean plasma half-lives were 13.2 ± 1.6 h for rhFIX and 13.3 ± 1.6 h for Mononine™. Dogs also received rhFIX (40 IU/kg IV, daily) for 28 days or Mononine™ (40 IU/kg IV daily) for 14 days. Anti-human Factor IX serum antibody levels were determined for each compound. Pharmacokinetic half-lives decreased in these treated dogs which developed antihuman Factor IX antibodies. The antibody responses in 28 day rhFIX (40 IU/kg) dogs were similar to 14 day Mononine™ (40 IU/kg) dogs.

 

  • References

  • 1 Thompson AR. Factor IX Concentrates for Clinical Use. Sem Thromb Hemostasis 1993; 19: 25-36
    Thieme ConnectPubMedSearch in Google Scholar
  • 2 Mannucci PM. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang 1993; 64: 197-203
    CrossrefPubMedSearch in Google Scholar
  • 3 Kaufman RJ, Wasley LC, Furie BC, Furie B, Shoemaker CB. Expression, purification, and characterization of recombinant gamma-carboxylated Factor IX synthesized in Chinese hamster ovary cells. J Biol Chem 1986; 261: 9622-9628
    PubMedSearch in Google Scholar
  • 4 Keith Jr JC, Rowles TK, Warwick K, Yau E. Acute gastric distention and volvulus in a Guinea pig anesthetized with xylazine and ketamine. Lab An Sei 1992; 42: 331-332
    PubMedSearch in Google Scholar
  • 5 McNeel SV, Hsu WH. Xylazine-induced prolongation of gastrointestinal transit in dogs: reversal by yohimbine and potentiation by doxapram. J Am Vet Med Assoc 1984; 185: 878-881
    PubMedSearch in Google Scholar
  • 6 Folkers ER. Xylazine precaution, letter. J Am Vet Med Assoc 1980; 176: 956
    PubMedSearch in Google Scholar
  • 7 Gerrard AJ, Austen EG, Brownlee GG. Subcutaneous injection of factor IX for the treatment of haemophilia B. Br J Haematology 1992; 81: 610-613
    CrossrefPubMedSearch in Google Scholar